Clinical trials: Hirsutism
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Hirsutism
Clinical Evaluation of Silk'n Glide for Face
This is a clinical study to determine the efficacy and safety of the Glide, hair removal photo-depilation device, for removing facial hairs.
- Trial name
- NCT02103608
- Testing
- Glide
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Home Skinovations Ltd.
Polycystic Ovary Syndrome, Menstrual Problem
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid.
- Conditions
- Polycystic Ovary Syndrome, Menstrual Problem, Hirsutism
- Trial name
- NCT03673995
- Testing
- Myo-inositol+L-tyrosine
- Where
- Italy
- Volunteers
- 186 people
- Sponsor
- Pharmarte srl
Hypertrichosis, Alopecia
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
A study to investigate clinical safety and effect on hair growth of FOL-005 in healthy volunteers. The study is divided in two parts, a single ascending dose (SAD) part and a multiple dose (MD) part.
- Conditions
- Hypertrichosis, Alopecia, Hirsutism
- Trial name
- NCT02793557
- Testing
- FOL-005
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Hirsutism, Hypertrichosis
Enhanced Safety Laser Hair Removal System
The purpose of this study is to determine whether a new laser system provides better safety and efficacy in hair removal than existing lasers.
- Trial name
- NCT00441948
- Testing
- Peterio
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Scilex Ltd.
Hirsutism
Evaluation of Eflornithine on Facial and Forearm Skin
The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms
- Trial name
- NCT00152048
- Testing
- Eflornithine hydrochloride
- Volunteers
- 78 people
- Sponsor
- Allergan
Hirsutism, Hypertrichosis
Enhanced Safety Aesthetic Laser System
The purpose of this study is to determine whether a new laser system provides better safety and efficacy than existing lasers in popular cosmetic procedures such as hair removal, treatment of cosmetically disturbing vascular…
- Conditions
- Hirsutism, Hypertrichosis, Telangiectases, Rhytides
- Trial name
- NCT00495443
- Testing
- Peterio
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Scilex Ltd.
Prostate Cancer, Hirsutism
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fed conditions.
- Trial name
- NCT00960310
- Testing
- Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA), Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Polycystic Ovary Syndrome (PCOS)
MLE4901 vs. Placebo for the Treatment of PCOS
This is a Phase 2b double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 versus placebo in women with PCOS.
- Trial name
- NCT02865915
- Testing
- MLE4901
- Where
- 31 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millendo Therapeutics US, Inc.
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Excessive Hairiness, Vascular Lesion
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias.
- Conditions
- Excessive Hairiness, Vascular Lesion, Pigmented Lesions, Acne Vulgaris
- Trial name
- Anthelia (NCT06655129)
- Testing
- intense pulsed light
- Where
- 5 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eurofeedback
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Prostate Cancer, Hirsutism
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fasting conditions.
- Trial name
- NCT00959335
- Testing
- Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA), Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz